Gordon J, McEwan P, Hurst M, Puelles J (2016) The cost-effectiveness of alogliptin versus sulfonylurea as add-on therapy to metformin in patients with uncontrolled type 2 diabetes mellitus
The medication is contraindicated in patients with uncontrolled hypertension, seizure disorders, or current use of MAO inhibitors
therefore, minor weight loss could be a side effect
the mechanistic rationale (BPC-157 favouring fibroblast and NO-mediated repair, T4 favouring actin dynamics, cell migration and angiogenesis) is entirely extrapolated from separate animal experiments
However, while these alleged benefits exist, scientific evidence supporting their efficacy still needs to be improved
Retatrutide is an investigational drug and is not FDA-approved for any indication